Abstract: An doxorubicin/lyposome composition which can be reconstituted from a lyophilized form to an injectable liposome suspension having selected liposome sizes in the size range between 0.1 and 0.5 microns, and between about 85-95% liposome-entrapped doxorubicin. The composition is prepared by reconstituting a lyophilized doxorubicin/liposome composition to a liposome concentrate, then diluting the concentrate for perenteral.

Abstract: A viral lysis immunoassay system and method. The system includes hemolytic particles carrying non-viral, anti-analyte molecules, lysable target cells which are devoid of surface molecules capable of binding to endogenous viral surface molecules, and foreign binding molecules added to the target cells. The binding molecules, which may be either analyte molecules or analyte-related molecules attached to the target cell surfaces, function to bind the particles to the cells, to initiate cell lysis and the release of encapsulated reporter molecules from the cells. The analyte to be assayed may be one adapted to bridge the virus particles to analyte-related molecules carried on the cell surfaces, or one which competes with target-cell molecules for binding to the particle anti-analyte molecules.